Ali Fattom Joins NanoBio to Lead the Company’s Vaccine Research Efforts: Ann Arbor-based NanoBio Corp. said Wednesday that Ali I. Fattom has joined the company as senior vice president of vaccine research and development. Fattom was previously vice president of research and early development at Nabi Biopharmaceuticals. In his new position, Fattom will draw upon his more than two decades of experience in vaccine research to lead NanoBio’s nanoemulsion-based intranasal and intramuscular vaccine programs. Fattom initiated his career as a vaccinologist at The National Institutes of Health where he helped develop several vaccines including a Pneumococcus conjugate vaccine and a S. aureus vaccine. More recently at Nabi, he played a key role in the development of a conjugate vaccine against Staphylococci and a vaccine against nicotine addiction. He earned a B.S. from The Hebrew University of Jerusalem, a M.S. in Microbiology from Tel-Aviv University, and a Ph.D. in Microbial Ecology from the Hebrew University of Jerusalem. Fattom is author of more than 50 peer reviewed publications, and holds more than 10 patents. NanoBio’s nanoemulsion-based vaccine adjuvant platform offers numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles. NanoBio’s vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. In 2010, the company successfully completed its first-in-man study of a nanoemulsion-adjuvanted intranasal vaccine, demonstrating safety and eliciting both mucosal and systemic immunity against seasonal influenza. More at www.nanobio.com.
(c) 2010, WWJ Newsradio 950. All rights reserved.